Audit: QRS - Safranal for Health & Longevity

Audit conducted on 16/08/2026 00:57 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol, time-to-effect, benefit and risk tiers, gates, all eight biomarkers and all five qualitative markers trace to ER Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications and Monitoring Protocol & Defining Success.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“Safranal alone has been given to people only once” and “mild and mostly reversible at the doses tested” mirror the ER Conclusion wording.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Pregnancy stays in the Contraindications gate, matching the ER avoid-list; no interaction was demoted or promoted.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER avoid-list, Key Interactions from the ER interaction bullets; no Benefit-Modifying Factors or Risk-Modifying Factors content was migrated.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, author names, NCT identifiers or brand names.
1.6	The QRS does not introduce new attributions.	🟢	No new sources, institutions or authorities are named.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, attribution-aware register matching the ER.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Targets, cadence and time-to-effect windows give actionable footing without hype.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Statements describe what trials did rather than instructing.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Protocol cells report the regimen used in trials; no directives.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise” or “should” constructions in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms retained are ER benefit/risk headings and biomarker names, where precision is required.
2.8	Information is presented in a concise and very compact manner	🟢	Every entry is a condensed phrase; no sentences carry rationale.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no “you”/”your” in the rendered text.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Standardisation target, biomarker panel and monitoring cadence assume a proactive self-optimiser.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Blood count, kidney panel and repeat symptom scoring are presented without softening.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content assumes lab access and sustained tracking.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance flags that effects concentrate “where values are already abnormal”, the key distinction for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Blood sugar” and “thinking” mirror the ER Conclusion; all other terms are formal (haematological, hepatocellular, orthostatic-relevant markers).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings, gate titles, tier labels and table headers are byte-identical to [qrs_template].
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables present; the repeatable marker_#_* and qualitative_item_# rows are expanded to 8 and 5 instances.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" spans, style block, and footer disclaimer are unmodified from the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that feeds the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard protocol”, “Best time of day” and “Standardisation target” match the ER Therapeutic Protocol bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring marker names match the ER biomarker table verbatim; time-to-effect labels track the ER “Time to effect” bullet’s own domains.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the QRS; the ER’s 🟩/🟥/🟨 and ⚠️ markers were stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Each ER bullet is reduced to a single short phrase; tier lists are collapsed to semicolon-separated runs rather than multiplied into rows.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text on line 2 precedes the block.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is echoed except the creation date and model in the standard subline.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, which the colon requires.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: safranal_2026-0825-2245_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02, matching QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0816-0020.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version only, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: safranal_2026-0825-2245_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Safranal for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Safranal for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0816-0020 → 08/16/2026.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only the title and the standard template subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses all four Conclusion paragraphs: extract-based evidence, mood/sleep effects, mild reversible risks, pregnancy boundary, single-dose attribution limit.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a distinct Conclusion sentence.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“Thinking”, “blood pressure”, “blood sugar”, “side effects” — no acronyms or clinical-register terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial identifiers or author names.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numerical results; only the qualitative “given to people only once”.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six entries come from the “Populations who should avoid Safranal” list in that section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER avoid-list populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six discrete <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	“Given absent human safety data” and similar rationale stripped; no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Weeks 1–20, platelet <100 × 10⁹/L, CKD stages 3b–5 with <45 mL/min/1.73 m², systolic <100 mmHg all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six avoid populations, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight entries map one-to-one onto the eight ER interaction bullets.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	No overlap with the Contraindications gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight discrete <li> elements.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Monitoring rationale (“additive lowering causes dizziness and falls”, “periodic full blood count is the safeguard”) stripped; no dash-trailing clauses.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named drug examples retained for every class, and the two-week pre-surgery window preserved; lists trimmed rather than dropped.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight interactions, and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells come from the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing and standardisation target — the three bullets that determine what is actually taken and when.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine sub-fields carry ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Mood/anxiety, sleep, and blood pressure/blood sugar — exactly the three domains in the ER “Time to effect” bullet.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	High tier (mood/anxiety) first, Medium (sleep) second, Medium/Low (blood pressure, glucose) third.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER names three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	4–6 weeks, 4–6 weeks and 8–12 weeks with ER-derived sublines.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect data, so the row is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All twelve benefit headings across the four tiers are represented.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the condensed ER heading; no magnitudes or mechanisms carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefit entry.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry items in the ER.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight risk headings across the four tiers are represented.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Median lethal doses, risk differences and culture concentrations are all omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk entry.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry items in the ER.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Drawn from Monitoring Protocol & Defining Success.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All eight ER table rows present with matching optimal ranges: blood pressure, haemoglobin, platelets, eGFR, fasting glucose, HbA1c, ALT, validated symptom score.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Baseline, symptom score at 4 and 12 weeks, blood pressure at 4 weeks, full blood count and kidney panel at 6 months then every 6–12 months — matching the ER narrative.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Taken from the “Qualitative markers worth tracking” list.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers present: sleep onset/wakings, morning alertness, daytime anxiety, appetite/snacking, dizziness on standing.

Issues 16/08/2026 00:57

Pass rate 100.00%. No issues found.

Issues 16/08/2026 00:51

1. 1.3 — Conditional risks stated as standalone: Three Monitoring “Why” cells drop the ER’s conditioning clauses — [marker_1_why] “hypotension risk” (ER: “the main additive-hypotension risk”), [marker_5_why] “hypoglycaemia risk” (ER: “additive hypoglycaemia risk on antidiabetic therapy”) and [marker_3_why] “Platelets fell in animals” (ER: “Platelets fell with prolonged high-dose animal exposure”); [marker_8_target] likewise reads “No target value” where the ER says “No established target value”.
2. 2.5 — Imperative in Key Interactions: The final [caution_items] entry (QRS line 582) reads “Scheduled surgery (stop two weeks before elective procedures)”, an instruction to the reader, where the ER states descriptively that the effects “argue for stopping two weeks before elective procedures”.

Fixes 16/08/2026 00:51

1. 1.3 — Additive hypotension qualifier restored: [marker_1_why] changed from “Primary cardiovascular effect; hypotension risk” to “Primary cardiovascular effect; additive hypotension risk”, matching the ER’s “additive-hypotension risk”.
2. 1.3 — Platelet finding re-conditioned: [marker_3_why] changed from “Platelets fell in animals” to “Platelets fell with prolonged high-dose animal exposure”, restoring the ER’s dose and duration context.
3. 1.3 — Hypoglycaemia risk re-conditioned: [marker_5_why] changed from “Saffron lowers fasting glucose; hypoglycaemia risk” to “Saffron preparations lower fasting glucose; additive hypoglycaemia risk on antidiabetic therapy”, per ER line 470.
4. 1.3 — Symptom-score target wording: [marker_8_target] changed from “No target value; track change from own baseline” to “No established target value; change from own baseline”, matching the ER and removing the imperative.
5. 2.5 — Directive removed from surgery interaction: [caution_items] final entry changed from “Scheduled surgery (stop two weeks before elective procedures)” to “Scheduled surgery (discontinuation two weeks before elective procedures)”, replacing the instruction with a descriptive noun phrase.

Issues 16/08/2026 00:42

1. 1.1 — Drug classes mis-nested in interactions: [caution_items] lines 581–582 collapse the ER’s two-level drug lists into a single parenthetical, so “Sedatives and hypnotics (benzodiazepines such as diazepam and alprazolam, zolpidem, alcohol)” reads as if zolpidem and alcohol were benzodiazepines, and “Antihypertensives (ACE inhibitors such as lisinopril, losartan, amlodipine, diuretics)” reads as if losartan, amlodipine and diuretics were ACE inhibitors; the ER (lines 324, 326) keeps them as separate classes.
2. 4.5 — Sheet exceeds one A4 page: Estimated rendered height is roughly twice the A4 content box, driven by the 8-row Monitoring table with 2–3-line “Why” cells (lines 641–763), the 8 two-line Key Interactions items (lines 580–592) and the 4-line [action_3_sub] (lines 483–487).

Fixes 16/08/2026 00:42

1. 1.1 — Drug classes mis-nested in interactions: Rewrote the two [caution_items] parentheticals so the ER’s class boundaries survive: “Sedatives and hypnotics (benzodiazepines, e.g. diazepam; zolpidem; alcohol)” and “Antihypertensives (ACE inhibitors, e.g. lisinopril; losartan; amlodipine; diuretics)”, replacing the flat comma lists that read as if zolpidem/alcohol were benzodiazepines and losartan/amlodipine/diuretics were ACE inhibitors.
2. 4.5 — Monitoring “Why” cells condensed: Shortened all seven multi-line “Why” cells to single-line phrasing (e.g. marker_7 from “Liver was spared in animal work, but the high-concentration hepatocyte signal warrants a reference value” to “Reference value for the liver-cell damage signal”) and trimmed [marker_8_target] to “No target value; track change from own baseline”.
3. 4.5 — Protocol panel condensed: Cut [action_3_sub] from four rendered lines to “Trial-protocol specification; lets the delivered dose be calculated”, trimmed [action_1_sub], and shortened [time_1_sub] and [time_3_sub] by dropping the redundant “in trials”.
4. 4.5 — Decision gates condensed: Reduced the kidney-disease contraindication to “Chronic kidney disease stages 3b to 5 (filtration rate below 45 mL/min/1.73 m²)” and trimmed the hypotension, hypersensitivity and antidiabetics entries, keeping every threshold, stage and named drug example.
5. 4.5 — Benefits, risks and cadence condensed: Compressed the Low-tier benefits list to verb-form entries, shortened the Speculative risk entry, and tightened [monitoring_cadence] and [qualitative_item_4] without dropping any ER item.

Issues 16/08/2026 00:35

1. 1.3 — Dose-scope qualifier dropped: [at_a_glance] (line 437) states “Side effects are mild and mostly reversible.”; the ER Conclusion (line 503) bounds the same statement as “The risks are mild and mostly reversible at the doses tested”, and the ER separately documents organ toxicity above that range, so the unqualified QRS wording strengthens the safety claim.

Fixes 16/08/2026 00:35

1. 1.3 — Dose-scope qualifier restored: Changed [at_a_glance] from “Side effects are mild and mostly reversible.” to “Side effects are mild and mostly reversible at the doses tested.”, matching the ER Conclusion; the closing sentence was trimmed to “Safranal alone has been given to people only once.” to stay within the 60-word budget (now 59 words).

Issues 16/08/2026 00:26

1. 1.3 — Reversibility hedge dropped: [at_a_glance] (line 437) states “Side effects are mild and reversible”, while ER line 503 says “mild and mostly reversible at the doses tested”; removing “mostly” strengthens the safety claim.
2. 2.5 — Prescriptive surgery instruction: [caution_items] line 591 gives the imperative “Scheduled surgery (stop two weeks before elective procedures)”, whereas ER line 338 only states the effects “argue for stopping two weeks before elective procedures”.

Fixes 16/08/2026 00:26

1. 1.3 — Reversibility hedge restored: Changed [at_a_glance] from “Side effects are mild and reversible” to “Side effects are mild and mostly reversible”, matching the ER’s hedged wording.
2. 2.5 — Prescriptive surgery instruction removed: Reworded the [caution_items] surgery entry from “Scheduled surgery (stop two weeks before elective procedures)” to “Scheduled surgery (discontinuation two weeks before elective procedures)”, preserving the time window without an imperative.